2021 Start-Up Stadium Winner!


Kayothera is targeting novel biology to reverse immune suppression and change the paradigm of cancer treatment by extending survival for patients with incurable cancers. We have developed first-in-class, orally available immunotherapies targeting a previously undruggable pathway that is responsible for immune suppression in solid cancers. In particular, our immunotherapeutic approach has the potential to treat soft-tissue sarcomas that currently have no effective standard of care. Press Release Available Here